Dysregulation of POPDC1 promotes breast cancer cell migration and proliferation

Johanna Ndamwena Amunjela, Steven John Tucker*

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Citations (Scopus)
4 Downloads (Pure)

Abstract

Breast cancer subtypes such as triple-negative that lack the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 receptor (HER2), remain poorly clinically managed due to a lack of therapeutic targets. This necessitates identification and validation of novel targets. Suppression of Popeye domain-containing protein 1 (POPDC1) is known to promote tumorigenesis and correlate to poor clinical outcomes in various cancers, and also promotes cardiac and skeletal muscle pathologies. It remains to be established whether POPDC1 is dysregulated in breast cancer, and whether overcoming the dysregulation of POPDC1 could present a potential therapeutic strategy to inhibit breast tumorigenesis. We assessed the potential of POPDC1 as a novel target for inhibiting breast cancer cell migration and proliferation. POPDC1 was significantly suppressed with reduced cell membrane localization in breast cancer cells. Furthermore, functional suppression of POPDC1 promoted breast cancer cell migration and proliferation, which were inhibited by POPDC1 overexpression. Finally, cAMP interacts with POPDC1 and up-regulates its expression in breast cancer cells. These findings suggest that POPDC1 plays a role in breast tumorigenesis and represents a potential therapeutic target or biomarker in breast cancer medicine.

Original languageEnglish
Article numberBSR20171039
JournalBioscience Reports
Volume37
Issue number6
Early online date21 Nov 2017
DOIs
Publication statusPublished - 22 Dec 2017

Fingerprint

BRCA1 Protein
Cell Movement
Cells
Cell Proliferation
Breast Neoplasms
Proteins
Carcinogenesis
Breast
Protein Domains
Progesterone Receptors
Bioelectric potentials
Biomarkers
Estrogen Receptors
Pathology
Cell membranes
Myocardium
Skeletal Muscle
Medicine
Up-Regulation
Therapeutics

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Dysregulation of POPDC1 promotes breast cancer cell migration and proliferation. / Amunjela, Johanna Ndamwena; Tucker, Steven John.

In: Bioscience Reports, Vol. 37, No. 6, BSR20171039, 22.12.2017.

Research output: Contribution to journalArticle

Amunjela, Johanna Ndamwena ; Tucker, Steven John. / Dysregulation of POPDC1 promotes breast cancer cell migration and proliferation. In: Bioscience Reports. 2017 ; Vol. 37, No. 6.
@article{403bb526b40a42b282c235d237de445b,
title = "Dysregulation of POPDC1 promotes breast cancer cell migration and proliferation",
abstract = "Breast cancer subtypes such as triple-negative that lack the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 receptor (HER2), remain poorly clinically managed due to a lack of therapeutic targets. This necessitates identification and validation of novel targets. Suppression of Popeye domain-containing protein 1 (POPDC1) is known to promote tumorigenesis and correlate to poor clinical outcomes in various cancers, and also promotes cardiac and skeletal muscle pathologies. It remains to be established whether POPDC1 is dysregulated in breast cancer, and whether overcoming the dysregulation of POPDC1 could present a potential therapeutic strategy to inhibit breast tumorigenesis. We assessed the potential of POPDC1 as a novel target for inhibiting breast cancer cell migration and proliferation. POPDC1 was significantly suppressed with reduced cell membrane localization in breast cancer cells. Furthermore, functional suppression of POPDC1 promoted breast cancer cell migration and proliferation, which were inhibited by POPDC1 overexpression. Finally, cAMP interacts with POPDC1 and up-regulates its expression in breast cancer cells. These findings suggest that POPDC1 plays a role in breast tumorigenesis and represents a potential therapeutic target or biomarker in breast cancer medicine.",
author = "Amunjela, {Johanna Ndamwena} and Tucker, {Steven John}",
note = "This work was funded by the University Of Aberdeen College Of Life Sciences and Medicine alongside the University of Aberdeen Elphinstone Scholarship Scheme. The authors thank Prof. Thomas Brand and Dr Roland Schindler at Imperial College London for the plasmid constructs and collaborative efforts. Finally, authors acknowledge Dr Jin Pu at the University of Aberdeen, for sharing the MCF10A and MDA231 cells.",
year = "2017",
month = "12",
day = "22",
doi = "10.1042/BSR20171039",
language = "English",
volume = "37",
journal = "Bioscience Reports",
issn = "0144-8463",
publisher = "Portland Press Ltd.",
number = "6",

}

TY - JOUR

T1 - Dysregulation of POPDC1 promotes breast cancer cell migration and proliferation

AU - Amunjela, Johanna Ndamwena

AU - Tucker, Steven John

N1 - This work was funded by the University Of Aberdeen College Of Life Sciences and Medicine alongside the University of Aberdeen Elphinstone Scholarship Scheme. The authors thank Prof. Thomas Brand and Dr Roland Schindler at Imperial College London for the plasmid constructs and collaborative efforts. Finally, authors acknowledge Dr Jin Pu at the University of Aberdeen, for sharing the MCF10A and MDA231 cells.

PY - 2017/12/22

Y1 - 2017/12/22

N2 - Breast cancer subtypes such as triple-negative that lack the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 receptor (HER2), remain poorly clinically managed due to a lack of therapeutic targets. This necessitates identification and validation of novel targets. Suppression of Popeye domain-containing protein 1 (POPDC1) is known to promote tumorigenesis and correlate to poor clinical outcomes in various cancers, and also promotes cardiac and skeletal muscle pathologies. It remains to be established whether POPDC1 is dysregulated in breast cancer, and whether overcoming the dysregulation of POPDC1 could present a potential therapeutic strategy to inhibit breast tumorigenesis. We assessed the potential of POPDC1 as a novel target for inhibiting breast cancer cell migration and proliferation. POPDC1 was significantly suppressed with reduced cell membrane localization in breast cancer cells. Furthermore, functional suppression of POPDC1 promoted breast cancer cell migration and proliferation, which were inhibited by POPDC1 overexpression. Finally, cAMP interacts with POPDC1 and up-regulates its expression in breast cancer cells. These findings suggest that POPDC1 plays a role in breast tumorigenesis and represents a potential therapeutic target or biomarker in breast cancer medicine.

AB - Breast cancer subtypes such as triple-negative that lack the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 receptor (HER2), remain poorly clinically managed due to a lack of therapeutic targets. This necessitates identification and validation of novel targets. Suppression of Popeye domain-containing protein 1 (POPDC1) is known to promote tumorigenesis and correlate to poor clinical outcomes in various cancers, and also promotes cardiac and skeletal muscle pathologies. It remains to be established whether POPDC1 is dysregulated in breast cancer, and whether overcoming the dysregulation of POPDC1 could present a potential therapeutic strategy to inhibit breast tumorigenesis. We assessed the potential of POPDC1 as a novel target for inhibiting breast cancer cell migration and proliferation. POPDC1 was significantly suppressed with reduced cell membrane localization in breast cancer cells. Furthermore, functional suppression of POPDC1 promoted breast cancer cell migration and proliferation, which were inhibited by POPDC1 overexpression. Finally, cAMP interacts with POPDC1 and up-regulates its expression in breast cancer cells. These findings suggest that POPDC1 plays a role in breast tumorigenesis and represents a potential therapeutic target or biomarker in breast cancer medicine.

UR - http://www.scopus.com/inward/record.url?scp=85039847001&partnerID=8YFLogxK

U2 - 10.1042/BSR20171039

DO - 10.1042/BSR20171039

M3 - Article

AN - SCOPUS:85039847001

VL - 37

JO - Bioscience Reports

JF - Bioscience Reports

SN - 0144-8463

IS - 6

M1 - BSR20171039

ER -